PUBLICATIONS

Grignani F., Ferrucci P.F., Testa U., Talamo G., Fagioli M., Alcalay M., Mencarelli A.,  Grignani  F., Peschle C., Nicoletti I., Pelicci P.G.: The Acute Promyelocytic Leukemia-specific PML-RARalpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, Aug 1993, Vol. 74, p. 423-31.

Dermine S., Grignani F., Clerici M., Nervi C., Sozzi G., Talamo G., Marchesi E., Formelli F., Parmini G., Pelicci P.G., Gambacorti-Passerini C.: Occurrence of resistance to retinoic acid in the Acute Promyelocytic Leukemia Cell Line NB4 is associated with altered expression of the PML/RARalpha protein. Blood, Sep 1, 1993. Vol. 82 (5), p. 1573-7.

Zangari M., Barlogie B., Thertulien R., Jacobson J., Eddleman P., Fink L., Fassas A., Van Rhee F., Talamo G., Lee C.-K., Tricot G.: Thalidomide and deep venous thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma, 2003; Vol. 4 (1), p. 32-5.

Lee C.-K., Zangari M., Barlogie B., Fassas A., van Rhee F., Thertulien R., Talamo G., Muwalla F., Anaissie E., Hollmig K., Tricot G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplantation, 2004; 33:823-8.

Miceli M.H., Jones Jackson L.B., Walker R.C., Talamo G., Barlogie B, Anaissie E.J. Diagnosis of infection of implantable central venous catheters by [­18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun, 2004; 25(8):813-8.

Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., Lee C.-K., Thertulien R., Talamo G., Thomas T., Van Rhee F., Fassas A., Fink L., Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

Talamo G., Angtuaco E., Walker R.C., Dong L., Miceli M.H., Zangari M., Tricot G., Barlogie B., Anaissie E. Avascular Necrosis of Femoral and/or Humeral Heads in Multiple Myeloma: Results of a Prospective Study of Patients Treated With Dexamethasone-Based Regimens and High-Dose Chemotherapy. J Clin Oncol, 2005 Aug 1; 23(22):5217-23.

Lee C.-K., Zangari M., Fassas A., Thertulien R., Talamo G., Badros A., Cottler-Fox M., van Rhee F., Barlogie B., Tricot G. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant, 2006; 37(5):511-5.

Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., Fassas A., Zangari M., Hollmig K., Pineda-Roman M., Lee C., Talamo G., Thertulien R., Kiwan E., Krishna S., Fox M., Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 2006; 354:1021-30.

Talamo G., Cavallo F., Zangari M., Barlogie B., Lee C.-K., Pineda-Roman M., Kiwan E., Krishna S., Tricot G. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica, 2006; 91:964-7.

Talamo G., Cavallo F., Zangari M., Barlogie B., Lee C.-K., Pineda-Roman M., Kiwan E., Krishna S., Tricot G. Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hemat, 2007; 82:414-5.

Talamo G., Claxton D., Tricot G., Fink L., Zangari M. Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol, 2008; 83:883-4.

Wozney J.L, Ahmed F., Ehmann W.C., Bayerl M.G., Talamo G. Skin involvement in IgE multiple myeloma. J Clin Oncol, 2009 Feb 1;27(4):637-8.

Farooq U., Bayerl M.G., Abendroth C.S., Verma N., Talamo G. Renal crystal storing histiocytosis in a patient with multiple myeloma. Ann Hematol, 2009; 88(8):807-9.

Talamo G., Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant. 2009 Aug;44(3):157-61.

Talamo G., Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis, 2009; 20(5):337-9.

Talamo G., Liao J, Bayerl MG, Claxton DF, Zangari M. Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy. Support Care Cancer. 2010 Mar;18(3):301-5.

Wozney JL, Damluji AA, Ahmed F, Zangari M, Loughran TP Jr, Talamo G. Estimation of Daily Proteinuria in Patients with Multiple Myeloma by Using the Protein-to-Creatinine Ratio in Random Urine Samples. Acta Haematol. 2010; 123(4):226-229.

Talamo G., Castellani W., Dolloff N.G. Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol 2010; 3:32.

Talamo G., Barochia A., Zangari M., Loughran TP. Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors. 2010 Mar 31;2(1):e4.

Talamo G., Farooq U., Zangari M., Liao J., Dolloff N.G., Loughran T.P. Jr., Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010 Dec 1;10(6):464-8.

Talamo G., Liao J., Joudeh J., Lamparella N., Malysz J., Ehmann W.C. Perceived levels of pain associated with bone marrow aspirates and biopsies. J Support Oncol, 2012; 10(4):166-70.

Talamo G., Rakszawski K.L., Rybka W.B., Dolloff N.G., Malysz J., Berno T., Zangari M. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol, 2012; 89(2):145-50.

Abbi K.K., Zhu J., Ehmann W.C., Epner E., Carraher M., Mierski J., Talamo G., Lucas K., Rybka W., Claxton D. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant, 2013; 48:357-62.

Talamo G., Dolloff N.G., Sharma K., Zhu Junjia, Malysz J. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors, 2012; 4:39.

Dolloff N.G., Allen J.E., Dicker D.T., Aqui N., Vogl D., Malysz J., Talamo G., El-Deiry W.S..Sangivamycin-Like Molecule 6 (SLM6) exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9 (CDK9). Mol Cancer Ther, 2012; 11:2321-30.

Dolloff N.G., Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol, 2013; 779:197-221.

Malysz J., Zhu J., Creer M.H., Dolloff N.G., Bayerl M.G., Talamo G. Retrospective study of quantitative free light chain levels in random urine of patients with multiple myeloma. J Hematol Malign, 2013; 3(2):8-15.

Talamo G., Zhu, J., Dolloff N.G., Lamparella, N.E., Joshi, M., Barochia, A., Drabick, J.J., Malysz, J. Retrospective study of body weight in patients with multiple myeloma through different stages of the disease. Metab Nutr Oncol, 2013. Published online, 2013, DOI http://dx.doi.org/10.1055/s-0033-1358760.

Pandey M.K., Kale V.P., Song C., Sung S.S., Sharma A.K., Talamo G., Dovat S., Amin S.G. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp Hematol, 2014; 42:883-96.

Cheng J., Talamo G., Malysz J., Ochmann M., Lamy T., P. Loughran T.P. Report of six cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e169-72.

Sommer I.E., van Bekkum D.W., Klein H., Yolken R., de Witte L., Talamo G. Severe chronic psychosis after allogeneic stem cell transplantation from a schizophrenic sibling. Bone Marrow Transplant, 2015; 50:153-4.

Al-Marrawi M.Y., Cream L.V., Mallon C.A., Holder S., Joshi M., Harvey H.H., Talamo G., Drabick J.J. Effect of Topical Vaginal Androgens in a Woman on the Testosterone Levels of Her Sexual Partner With Prostate Cancer. J Clin Oncol, 2015; 33:521-2.

Talamo G., Mir M.A., Pandey M.K., Sivik J.K., Raheja D. IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol, 2015; 94:1011.

Talamo G., Dimaio C., Abbi K.K., Pandey M.K., Malysz J., Creer M.H., Zhu J., Mir M.A., Varlotto J.M. Current role of radiation therapy for multiple myeloma. Front Oncol, 2015; 5:40.

Wyluda E.J., Cheng J., Schell T.D., Haley J.S., Mallon C., Neves R.I., Robertson G., Sivik J., Mackley H., Talamo G., Drabick J.J. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther, 2015; 16:662-70.

Patel U.H., Mir M.A., Sivik J.K., Raheja D., Pandey M.K., Talamo G. Central neurotoxicity of immunomodulatory drugs in multiple myeloma. Hematol Rep. 2015; 7:5704.

Pandey M.K., Amin S.G., Zangari M., and Talamo G. Drug resistance in multiple myeloma: how to cross the border. Ann Hematol Oncol, 2015; 2(2):1025.

Wang W., Cheng J., Mallon C., Al-Marrawi M.Y., Holder S., Joshi M., Kaag M., Talamo G., Drabick J.J. Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review. Clin Genitourin Cancer. 2015; 13:e391-5.

Talamo G., Sivik J., Pandey M.K., Mir M.A. Bortezomib-induced acute pancreatitis: Case report and review of the literature. J Oncol Pharm Pract. 2016; 22(2):332-4.

Malysz J., Talamo G., Zhu J., Clarke L.E., Bayerl M.G., Ali L., Helm K.F., Chung C.G. Cutaneous involvement in multiple myeloma (MM): A case series with clinicopathologic correlation. J Am Acad Dermatol. 2016 May;74(5):878-84.

Pandey M.K., Gowda K., Sung S.S., Abraham T., Budak-Alpdogan T., Talamo G., Dovat S., Amin S. A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis. Exp Hematol. 2017 Sep; 53:31-42.

 

ABSTRACTS

Alcalay M., Lanfrancone L., Montanucci M., Talamo G., Grignani F., Pelicci P.G.: Structure and function of the c-fes oncogene. Oncogenes and growth factors in oncohematology. Edited by M. Aglietta, G. Saglio, F. Gavosto; p. 97-100. 1988.

M. Alcalay, G. Talamo, F. Grignani, P.G. Pelicci: Caratterizzazione strutturale dell' oncogene c-fes. Primo Incontro Nazionale della Società Italiana di Ematologia Sperimentale. Milano, Italy, 27 May 1988.

Alcalay M., Lanfrancone L., Talamo G., Grignani F., Pelicci P.G.: Expression pattern and structure of the human c-fes oncogene. Oncogenes and growth control. Heidelberg, Sept. 1988. Edited by EMBL.

Pelicci P.G., Lanfrancone L., Alcalay M., Montanucci M., Talamo G., Grignani F.: Expression pattern and structure of the human c-fes oncogene. Fourth Annual Meeting on Oncogenes. Frederick, Maryland, 1988.

Fagioli M., Alcalay M., Pandolfi P., Venturini L., Talamo G., Mencarelli A., Pelicci P.G.: Three potentially oncogenic proteins (PML/RAR, aberrant PML and RAR/PML) are generated by the Acute Promyelocytic Leukemia 15;17 translocation. Eighth Annual Meeting on Oncogenes. Frederick, Maryland, 1992.

Grignani F., Ferrucci P.F., Alcalay M., Talamo G., Mencarelli A., Grignani F., Pelicci P.G.: Biological function of the Acute Promyelocytic Leukemia (APL) t(15;17) translocation products. AACR Genetics of Cancer, Nov. 1992. Hilton Head, South Carolina, USA.

Ferrucci P.F., Alcalay M., Fagioli M., Talamo G., Mencarelli A., Grignani F., Pelicci P.G.: Expression of the Acute Promyelocytic-Leukemia (APL) translocation product into human myeloid cell lines. Keyston Symposia on Molecular & Cellular Biology. January 1993.

Talamo G., Pesenti Compagnoni M.: Infarto splenico: una rara complicazione del flutter atriale [Splenic infarct: a rare complication of atrial flutter]. Fifth National Congress of the Italian Federation of Emergency Medicine. Bologna, Italy, Nov. 1999.

Barlogie B., Jacobson J., Anaissie E., Fassas A., Lee C.-K., Thertulien R., Tricot G., Van Rhee F., Zangari M, Talamo G., McCoy J., Crowley J.: Post-transplant consolidation therapy toward improving long-term disease-free survival: preliminary results of total therapy II (TTII). IX International Multiple Myeloma Workshop. Salamanca, Spain, 2003; vol. 4 (suppl. 1) S73, Abstract #.P11.3.2

Lee C.-K., Barlogie B., Zangari M., Fassas A., Van Rhee F., Thertulien R., Talamo G., Cottler-Fox M., Tricot G.: Durable disease control of high-risk myeloma with allotransplantation after reduced intensity conditioning (RIC) is only achieved when applied early in the disease course after optimal tumor reduction. Proc. Am. Soc. Clin. Oncol., 2003; vol. 22, Abstract #2345.

Zangari M., Barlogie B., Thertulien R., Jacobson J., Eddleman P., Fink L., Fassas A., Talamo G., Cottler-Fox M., Tricot G: Durable disease control of high-risk myeloma with allotransplantation after reduced intensity conditioning (RIC) is only achieved when applied early in the disease course after optimal tumor reduction. Proc. Am. Soc. Clin. Oncol., 2003; vol. 22, Abstract #2347.

Lee C.K., Barlogie B., Kang S.-H., Epstein J., Shaughnessy J., Zangari M., Fassas A., Cottler-Fox M.H., Van Rhee F., Thertulien R., Talamo G., Anaissie E.J., Tricot G. Proliferative, Cytogenetic and Gene Cluster Characteristics of Myeloma Phenotype. Blood, 2003; 102(11): Abstract #1623.

Anaissie E.J., Jacobson J., Fassas A., Zangari M., Thertulien R., Van Rhee F., Talamo G., Tricot G., Wendling C., Davis C.K., Hollmig K., Barlogie B. Safety of Total Therapy II with or without Thalidomide (THAL) for Newly Diagnosed Myeloma: A Study of 475 Consecutive Patients. Blood, 2003; 102(11): Abstract #1657.

Lee C.K., Barlogie B., Kang S.-H., Shaughnessy J., Zangari M., Fassas A., Epstein J., Van Rhee F., Thertulien R., Talamo G., Cottler-Fox M.H., Anaissie E.J., Tricot G. Presence of High (10%) Ki67+ Myeloma Cells Is Associated with CD117- Phenotype, Abnormal Chromosomes and Agressive Myeloma Gene Clusters, and Portends a Poor Outcome after Autotransplant. Blood, 2003; 102(11): Abstract #2527.

Thertulien R., Jacobson J., McCoy J., Ojha R., Zangari M., Fassas A., Anaissie E., Van Rhee F., Talamo G., Lee C.-K., Crowley J., Tricot G., Barlogie B. Impact of Cytogenetics of Focal Lesions Biopsied by Fine Needle Aspiration Versus Bone Marrow in Myeloma Patients. Blood, 2003; 102(11): Abstract #2529.

Fassas A., Sawyer J., McCoy J., Anaissie E.J., Lee C.K., Talamo G., Wendling C., Zangari M., Van Rhee F., Thertulien R., Tricot G., Barlogie B. Absence of Hypodiploidy and/or Chromosome 13 Abnormalities (hypo-CA13) Confers Superior Survival in Multiple Myeloma (MM) Patients (pts): Interim Analysis of Total Therapy (TT) II Trial. Blood, 2003; 102(11): Abstract #2534.

Zangari M., Barlogie B., Lee C.-K., Kang S.-H., Fassas A., Thertulien R., Van Rhee F., Talamo G., Burns M., Anaissie E.J., Tricot G., Jacobson J. Increment in Bone Phophatase (ALP) in Myeloma Patients during Treatment with Velcade, Thalidomide and Dexamethasome (VTD) Is a Strong Predictor for Response. Blood, 2003; 102(11): Abstract #2544.

Zhan F., Kordsmeier B., Thertulien R., Zangari M., Lee C.-K., Talamo G., Fassas A., Anaissie E.J., VanRhee F., Tricot G.J., Barlogie B., Shaughnessy J. Prediction of Two-Year Survival of Patients with Myeloma Treated with Total Therapy II Using a Multivariate Discriminate Model of Gene Expression. Blood, 2003; 102(11): Abstract #3483.

Lee C.K., Barlogie B., Kang S.-H., Epstein J., Shaughnessy J., Zangari M., Fassas A., Cottler-Fox M.H., Van Rhee F., Thertulien R., Talamo G., Anaissie E.J., Guido Tricot. CD52+CD117- Myeloma Phenotype Is Associated with High Risk for Relapse in Newly Diagnosed Patients. Blood, 2003; 102(11): Abstract #3485.

Barlogie B., Rasmussen E., Fassas A., Zangari M., Anaissie E., Lee C.-K., Thertulien R., Van Rhee F., Talamo G., Tricot G. Tandem autotransplants (AT) for multiple myeloma (MM): Single center experience with >2000 patients. Proc. Am. Soc. Clin. Oncol., 2004; vol. 23, Abstract #6537.

Zhan F., Sawyer J., Gupta S., Huang Y., Anaissie E., Xu H., Hanamura I., Santra M., Zangari M., Lee C.K., Fassas A., van Rhee F., Hollmig K., Talamo G., Thertulien R., Tricot G., Barlow W., Rasmussen E., Crowley J., Barlogie B., Shaughnessy J. Elevated expression of CKS1B at 1q21 is highly correlated with short survival in myeloma. Blood, 2004; 104(11): Abstract #77.

Zhan F., Kapp S., Huang Y., Anaissie E., Xu H., Hanamura I., Sawyer J., Santra M., Lee C-K., Fassas A., van Rhee F., Hollmig K., Talamo G., Thertulien R., Tricot G., Barlow W., Rasmussen E., Crowley J., Barlogie B., Shaughnessy J. Serial gene expression studies of malignant plasma cells before treatment and after relapse: identifying genes linked to drug resistance in myeloma. Blood, 2004; 104(11): Abstract #784.

Hollmig K., Stover J., Talamo G., Zangari M., Thertulien R., van Rhee F., Fassas A., Anaissie E., Tricot G., Barlogie B. Addition of bortezomib (VelcadeTM) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM). Blood, 2004; 104(11): Abstract #929.

Fassas A., Barlogie B., Rasmussen E., Milner T., Terry J., Zangari M., Talamo G., Lee C.K., Thertulien R., Crowley J., Tricot G. Low incidence of complete remission but comparable free survival (EFS) and overall survival (OS) with a history of prior monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) among patients receiving Total Therapy 2 (TT2). Blood, 2004; 104(11): Abstract #932.

Thertulien R., Barlogie B., Zangari M., Fassas A., Stover J., Milner T., Anaissie E., Lee C.K., Hollmig K., Talamo G., Tricot G. Total Therapy 2 (TT2) for newly diagnosed patients with multiple myeloma (MM): examination of dose effect of thalidomide (T) among those randomized to T. Blood, 2004; 104(11): Abstract #934.

Anaissie E., Miceli M.H., Dong L., Saghafifar F., Talamo G., Hollmig K., Tricot G., Barlogie B. Safety of Total Therapy III for newly diagnosed multiple myeloma: preliminary analysis of 62 consecutive patients. Blood, 2004; 104(11): Abstract #935.

Tricot G., Crowley J., Stover J., Milner T., Fassas A., Zangari M., Thertulien R., Anaissie E., van Rhee F., Talamo G., Hollmig K., Barlogie B. Lack of prognostic implications of induction response to Total Therapy 2 (TT-2) in newly diagnosed patients with multiple myeloma (MM) for post-transplant event-free survival (EFS) and overall survival (OS). Blood, 2004; 104(11): Abstract #936.

Anaissie E., Miceli M.H., Dong L., Grazziutti M.L., Rajan S., Talamo G., Thertulien R., Fassas A., Tricot G., Barlogie B. Increased bone marrow iron stores, severe mucositis and large area under the curve (AUC) of profound neutropenia predict severe infection in 382 myeloma patients undergoing melphalan – autologous stem cell transplantation (MEL-ASCT). Blood, 2004; 104(11): Abstract #1158.

Zangari M., Barlogie B., Hollmig K., Fassas A., Rasmussen E., Thertulien R., Talamo G., Lee C.K., Tricot G. Marked activity of Velcade + Thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood, 2004; 104(11): Abstract #1480.

Hollmig K., Stover J., Talamo G., Fassas A., Lee C.K., Anaissie E., Tricot G., Barlogie B. Bortezomib (VelcadeTM) + AdriamycinTM + Thalidomide + Dexamethasone (VADT) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood, 2004; 104(11): Abstract #2399.

Anaissie E., Talamo G., Angtuaco E., Walker R.C., Dong L., Zangari M., Tricot G., Barlogie B. Avascular necrosis of bone after therapy for multiple myeloma: a study of 561 consecutive patients. Blood, 2004; 104(11): Abstract #3467.

Zangari M., Barlogie B., Lee C-K., Tricot A., Fassas A., Anaissie E., Hollmig K., Thertulien R., Talamo G., van Rhee F., Stover J., Fink L., Tricot G. Protective effect of Velcade® on thalidomide-associated deep venous thrombosis (DVT). Blood, 2004; 104(11): Abstract #4914.

Shaughnessy J., Zhan F., Barlogie B., Rasmussen E., Milner T., Jackson L., Fassas A., Zangari M., Lee C.K., Talamo G., Thertulien R., Crowley J., Tricot G. Metaphase cytogenetic abnormalitites (m-CA) and interphase FISH for deletion 13 (FISH 13) in Total Therapy 2 (TT 2): follow up observation among 380 patients with newly diagnosed multiple myeloma (MM). Blood, 2004; 104(11): Abstract #4935.

Anaissie E., Grazziutti M., Fassas A., Dong L., Miceli H., van Rhee F., Hollmig K., Talamo G., Tricot G., Barlogie B. Daily C-Reactive Protein (CRP) levels allow early identification of patients with severe complications after melphalan (MEL) and autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Blood, 2004; 104(11): Abstract #5040.

Hollmig K.A., Stover J.M., Fox M.C., Jackson L.C., Talamo G., Fassas A., Zangari M., Lee C.K., van Rhee F., Anaissie E., Tricot G., Barlogie B. Collection of peripheral blood stem cells in 668 patients with multiple myeloma treated on Total Therapy II (UARK 98-026). Blood, 2004; 104(11): Abstract #5236.

Barlogie B., Tricot G., Shaughnessy J., Rasmussen E., Zhan F., Anaissie E., Zangari M., Talamo G., Zeldis J., Crowley J. Results of Total Therapy II (TT2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM). Proc. Am. Soc. Clin. Oncol., 2005; vol. 23, Abstract # 6502.

Fassas A., Barlogie B., Ward S., Rasmussen E., van Rhee F., Zangari M., Lee C.K., Talamo G., Thertulien R., Fox M., Tricot G. High-dose treatment (HDT) and autologous stem cell transplant (ASCT) in Waldenstrom’s macroglobulinemia (WM) patients (pts): A single center experience. Proc. Am. Soc. Clin. Oncol., 2005; vol. 23, Abstract # 6661.

Lee C.K., Zangari M., Fassas A., Cottler-Fox M., van Rhee F., Thertulien R., Talamo G., Barlogie B., Tricot G. Progressive clonal cytogenetic changes associated with myeloma relapse after allogeneic transplantation following reduced intensity conditioning. Proc. Am. Soc. Clin. Oncol., 2005; vol. 23, Abstract # 6663.

Talamo G., Zhang W., Bayerl, M. Oral analgesia and anxiolysis for pain associated with bone marrow biopsy. J Clin Oncol 26: 2008 (May 20 suppl; Abstract#20605).

Talamo G., Claxton D.F., Drabick J., Dougherty D.W., Sivik J., Ehmann W.C., Rybka W. Single autologous stem cell transplant using busulfan and cyclophosphamide as conditioning regimen in patients with multiple myeloma. Blood, 2008; 112(11): Abstract #4436.

Kura R, Ghahramani N, Talamo G. Correlation between spot urinary protein to creatinine ratio and 24-hour proteinuria in patients with multiple myeloma. Blood Purif 2009;27:144 - Abstract #17.

G. Talamo, D.F. Claxton, W.C. Ehmann, J Mierski, W. Rybka, S. Ibrahim. Effect of mobilization chemotherapy with cyclophosphamide and etoposide on stem cell collection by lenalidomide. J Clin Oncol 27: 2009 (May 20 suppl; Abstract#7096 - Poster presentation at ASCO 2009).

Karch J., Schaefer E., Ehmann W.C., Carraher M., Talamo G., Rybka W.B., Claxton D.F.. Long term survival after sirolimus based non-ablative alternative donor transplantation. Blood, 2009; 114: Abstract#1212 (Poster presentation at ASH 2009).

Abbi K.K.S., Ehmann W.C., Talamo G., Lucas K., Carraher M., Rybka W., Claxton D. G-CSF mobilized versus conventional donor lymphocytes in the treatment of hematological malignancies. Blood, 2009; 114: Abstract #4301.

Zheng H., Carraher M., Schaefer E., Talamo G., Ehmann W.C., Rybka W., Claxton D.F. Sirolimus for Graft-Versus-Host-Diseases prophylaxis in non-myeloablative matched related transplantation: safety and efficacy. Blood, 2009; 114: Abstract #4329.

Abbi K.K., Wagner H., Drabick J.J., Loughran T.P., Talamo G. The role of radiation therapy for multiple myeloma in the era of novel agents. J Clin Oncol 28, 2010 (suppl; abstr e18557) (ASCO 2010).

Rakszawski K.L., Drabick J.J., Sivik J., Dolloff N.G., Ehmann W.C., Rybka W., Talamo G. High-dose melphalan on day -2 vs -1 before autologous stem cell transplantation for multiple myeloma. J Clin Oncol 29, 2011 (May 20 suppl; Abstract #6545 - Poster presentation at ASCO 2011).

Dolloff N.G., Talamo G., Dicker D.T., El-Deiry W.S.. Sangivamycin-Like Molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb. 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. November 12-16, 2011 – San Francisco, CA. Abstract #C77.

Talamo G., Ali L., Clarke L.E., Helm K.F., Bayerl M.G., Malysz J. Cutaneous involvement of plasma cell neoplasms. 48th Annual Meeting of The American Society of Dermatopathology (ASDP). J Cutan Pathol, 2012: 39: 101-2.

Talamo G., Ehmann W.C., Dolloff N.G., Malysz J., Drabick J.J., Rybka W.B. Retrospective analysis of second malignancies in patients with multiple myeloma. J Clin Oncol 30, 2012 (May 20 suppl; Abstract 8090 - Poster presentation at ASCO 2012).

Zangari M., Berno T., Talamo G., Zhan X., Zhou W., Wang H., Yang Y., Xia J., Zhou Y., Pena K., Lujan L., Kohan J., Salama M.E., Zhan F. Phase I exploratory study of IV formulation of panobinostat in combination with bortezomib in relapsed/refractory multiple myeloma patients: effect on serum PTH and gene expression profiling (GEP) studies. Blood, Nov 2012; 120: 4073 (Poster presentation at ASH 2012).

Sivik J.M., Whaley S., Mierski J., Castellani W.J., Lowe M., Zhu J., George M., Rybka W.B., Talamo G. Comparison of four different strategies of stem cell mobilization in patients with multiple myeloma. J Clin Oncol 31, 2013 (suppl; abstr 7039 - Poster presentation at ASCO 2013).

Drabick J.J., Lapsiwala R., Talamo G., Epner E., Supko J.G., Claxton D., Ehmann W.C., Lander M., St. Pierre M., Rybka W.B. A phase II pilot efficacy trial of the combination regimen peg asparaginase/peg liposomal doxorubicin/dexamethasone (ODD) in patients with refractory lymphoid malignancies (NCT00837200). J Clin Oncol 31, 2013 (suppl; abstr e19502).

Zangari M., Berno T., Salama M.E., Sana S., Talamo G., Pena K., Miller S., Zhan F. Effect of low dose bortezomib on bone formation in smoldering myeloma patients. Blood, 2013; 3204 (Oral and Poster presentation at ASH 2013).

Talamo G., Zhu J., Drabick J.J., Pandey M.K., Dolloff N.G., Creer M.H., Malysz J. Protein/creatinine ratio in random urine instead of 24-hour urine collections for the assessment of renal involvement in patients with amyloidosis. J Clin Oncol 32, 2014 (suppl; abstr e19591) (ASCO 2014).

Kopp M. and Talamo G. Weighing in: Actual vs Ideal vs Adjusted Body Weight to calculate dose of melphalan in patients with multiple myeloma undergoing autologous autologous stem cell transplantation. Abstract #38, Onc Nursing F 42 (2), March 2015 (Poster at the Oncology Nursing Society Annual Congress, 2015).

 

 

BOOK CHAPTERS

Talamo G. Pathophysiology of Emergency Illness Due to Cancer. Chapter 5. In: J.F. Holland, E. Frei. Oncologic Emergencies. Edited by S.J. Yeung and C. Escalante. Brian Decker Publishing, 2002.

Talamo G. Pathophysiology of Emergency Illness Due to Treatment of Cancer. Chapter 6. In: J.F. Holland, E. Frei. Oncologic Emergencies. Edited by S.J. Yeung and C. Escalante. Brian Decker Publishing, 2002.

Talamo G. and Zangari M. Novel therapeutic approaches to cryoglobulinemia: Imatinib, Infliximab, Bortezomib and beyond. In: HCV infection and cryoglobulinemia. Edited by F. Dammacco. Springer, 2012. pp. 349-55.

 

 


Giampaolo Talamo, M.D.